A Polysomnographic Study of Parkinson’s Disease Sleep Architecture
Table 3
Multiple linear logistic regression models showing the independent association among demographic and clinical variables and the sleep parameters of PD patients.
Variable
coefficients
95% CI
“” value
Sleep efficiency
Constant
105.17 (13.57)
<0.0001
Amantadine
−11.37 (6.29)
−24.0 to 1.26
0.07
Age, years
−0.57 (0.22)
−1.0 to −0.14
0.01
r = 0.41; adjusted
0.008
Stage 1%
Constant
18.49 (2.73)
13.03 to 23.96
<0.0001
Dopamine agonist
−9.08 (3.03)
−15.17 to −2.99
0.004
Severe H&Y stagea
15.90 (5.13)
5.57 to 26.24
0.003
r = 0.49; adjusted
0.01
Stage 2%
Constant
67.22 (2.82)
61.55 to 72.88
<0.0001
MAO-B inhibitorsb
−16.25 (6.85)
−29.98 to −2.51
0.02
MDS-UPDRS IIIc
−11.67 (0.44)
−20.47 to −2.66
0.01
r = 0.42; adjusted
0.007
Stage 3%
Constant
10.77 (1.77)
7.23 to 14.32
<0.0001
MAO-B inhibitorsb
8.75 (4.29)
0.14 to 17.35
0.04
MDS-UPDRS IIIc
4.69 (2.78)
−0.89 to 10.27
0.09
r = 0.33; adjusted
0.05
REM stage %
Constant
26.2 (5.73)
14.69 to 37.68
<0.0001
Age
−0.21 (0.09)
−0.39 to −0.02
0.02
r = 0.30; adjusted
0.03
Total sleep time, minutes
Constant
329.05 (18.26)
292.42 to 365.69
<0.0001
Male
58.59 (28.95)
0.48 to −116.70
0.05
Severe H&Y stagea
−109.58 (61.95)
−233.90 to −14.73
0.08
r = 0.35; adjusted
0.03
aH&Y = Hoehn & Yahr stage. Moderate and severe affected patients were grouped as severe H&Y stage; bMAO-B = monoamine oxidase type B; cMDS-UPDRS = Movement Disorders Society-Unified Parkinson’s Disease Rating Scale, Part III.
